{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-23-007315","form_type":"8-K","ticker":null,"cik":"0001792581","company_name":"Kiromic Biopharma, Inc.","filed_at":"2023-04-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.619632+00:00","generated_at":"2026-06-16T06:39:27.835372+00:00","sec_items":["1.01","2.03","3.02","9.01"],"event_type":"debt","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Kiromic BioPharma issues $2M 25% senior secured convertible note due April 2024","bullets":["Principal $2M; interest 25% per annum (27% on default); matures April 25, 2024.","Convertible at $6.50 per share, subject to 9.99% beneficial ownership limitation and share cap (0.1999 × 979,243 shares).","Note secured by all fixtures, equipment, and intellectual property of the company.","Issued to an accredited investor under Section 4(a)(2) exemption from registration.","Company may incur additional debt that is senior, pari passu, or junior to this note."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-23-007315","json":"https://secwatch.observer/filing/0001558370-23-007315.json","markdown":"https://secwatch.observer/filing/0001558370-23-007315.md","text":"https://secwatch.observer/filing/0001558370-23-007315.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1792581/000155837023007315/0001558370-23-007315-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1792581/000155837023007315/krbp-20230425x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-16T06:39:27.835372+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"bf4067609a38ea1d406ecf9b20456d3408e01aad","claim":"Kiromic Biopharma, Inc. incurred convertible notes of $2,000,000 with an accredited investor at 25% per annum maturing April 25, 2024.","evidence_excerpt":"On April 25, 2023, Kiromic BioPharma, Inc. (the “Company”) issued a 25% Senior Secured Convertible Promissory Note (the “Note”) to an accredited investor. The Note has a principal amount of $2,000,000, bears interest at a rate of 25% per annum (the “Stated Rate”) and matures on April 25, 2024 (the “Maturity Date”)","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/1792581/000155837023007315/0001558370-23-007315-index.htm","confidence":0.9,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"convertible notes"},{"label":"Principal","value":"$2,000,000"},{"label":"Counterparty","value":"an accredited investor"},{"label":"Rate","value":"25% per annum"},{"label":"Maturity","value":"April 25, 2024"},{"label":"Event","value":"incurrence"}],"fact_type":"debt_financing"},{"claim_id":"c3d9f73d3719bccf8a9179a35e94a11353e27ade","claim":"Kiromic Biopharma, Inc. entered into 25% Senior Secured Convertible Promissory Note with accredited investor valued at $2,000,000 (effective 2023-04-25).","evidence_excerpt":"On April 25, 2023, Kiromic BioPharma, Inc. (the “Company”) issued a 25% Senior Secured Convertible Promissory Note (the “Note”) to an accredited investor. The Note has a principal amount of $2,000,000","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1792581/000155837023007315/0001558370-23-007315-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"notes offering"},{"label":"Counterparty","value":"accredited investor"},{"label":"Value","value":"$2,000,000"},{"label":"Effective","value":"2023-04-25"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}